Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

Sponsor
Abbott
Study ID
NCT00647920
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • adalimumab — BIOLOGICAL
    40 mg adalimumab sc, every other week
  • placebo — BIOLOGICAL
    placebo sc, every other week

Study Details

A Randomized, Double-Blind, Placebo-Controlled, Study of the Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated with Methotrexate

Key Dates

Start date
Jul 31, 2003
Status verified
Mar 2008
Primary completion
Apr 30, 2005

Study Design

Enrollment
47 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 40 mg
  • Placebo Comparator: Placebo

Primary Outcome Measure

ACR20 [ Time Frame: Week 12 ]

Related Studies